{"id":4882,"date":"2026-02-13T15:45:19","date_gmt":"2026-02-13T15:45:19","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/4882\/"},"modified":"2026-02-13T15:45:19","modified_gmt":"2026-02-13T15:45:19","slug":"roche-settles-perjeta-patent-suit-on-organon-henlius-biosimilar","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/4882\/","title":{"rendered":"Roche Settles Perjeta Patent Suit on Organon, Henlius Biosimilar"},"content":{"rendered":"<p>Roche Holding AG subsidiaries have settled their patent suit over Shanghai Henlius Biotech Inc. and Organon &amp; Co.&#8217;s biosimilar version of the blockbuster breast-cancer drug Perjeta, the companies said in a federal court filing.<\/p>\n<p>The Swiss company\u2019s Genentech Inc. and Hoffmann-La Roche Inc. units and the co-defendants agreed to dismiss all claims and counterclaims, closing the door on any chance to renew allegations, according to their <a href=\"https:\/\/www.bloomberglaw.com\/public\/document\/GENENTECHINCetalvSHANGHAIHENLIUSBIOTECHINCetalDocketNo225cv14648D\/2?doc_id=X3K3BG4ON339AMRJN88OKG1PFLQ\" rel=\"nofollow noopener\" target=\"_blank\">proposed joint stipulation of dismissal<\/a> filed Thursday in the US District Court for the District of New Jersey. <\/p>\n<p>The filing provided no further details on the agreement. <\/p>\n<p>The US Food and Drug Administration <a href=\"https:\/\/aboutblaw.com\/bkM5\" rel=\"nofollow noopener\" target=\"_blank\">approved &#8230;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG subsidiaries have settled their patent suit over Shanghai Henlius Biotech Inc. and Organon &amp; Co.&#8217;s&hellip;\n","protected":false},"author":2,"featured_media":4883,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[4195,4192,4193,4194,4196,4189,4197,4191,4190,134,1763],"class_list":{"0":"post-4882","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-biosimilars","9":"tag-biotechnology-patents","10":"tag-counterclaims","11":"tag-drug-approval-process","12":"tag-patent-infringement","13":"tag-patent-licensing","14":"tag-patent-term","15":"tag-pharmaceutical-patents","16":"tag-prescription-drugs","17":"tag-roche","18":"tag-settlements"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/4882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=4882"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/4882\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/4883"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=4882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=4882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=4882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}